Carla van Alem, MSc

After kidney transplantation an episode of acute rejection is a major complication which can lead to a decrease in graft function. Currently, acute rejection is treated with high doses of systemic methylprednisolone. Although this therapy is effective, it can also lead to severe side effects such as osteoporosis, diabetes mellitus type II, and opportunistic infections. A way to circumvent the occurence of systemic side effects is by delivering the drug locally, using the immune system to lead the drug to the target site. Liposomal prednisolone is a formulation where metyhlprednisolone is encapsulated in a lipid bilayer. This molecule is then phagocytosed by macrophages at the site of inflammation, and thereby deliveres the methylprednisolone to these tissues tissues. The effect of this formulation on acute rejection after kidney transplantation is studied pre-clinically and will be followed by a clinical study.